Related Experiment Video
Updated: Nov 27, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Bladder cancer immunological background and biomarkers.]
Mar Valés-Gómez1, Gloria Esteso1, María José Felgueres1
1Departamento de Inmunología y Oncología. Centro Nacional de Biotecnología (CNB-CSIC). Madrid. España.
Abstract:
Bladder cancer was one of the first to have a successful treatment based on immune system stimulation, recognized by patient survival and tumor recurrence data. In addition, bladder tumors are now known to have high antigenic load and are therefore considered to be susceptible to respond well to new immunotherapies. For these reasons, studying the mechanism of action of bladder cancer immunological-based treatments can provide valuable information both to improve their current use and to under stand why they work in some patients while others do not tolerate this therapy or have tumor progression. In this article, we will focus on the immune response generated by treatment of non-muscle invasive bladder tumors with BCG, as well as the relationship between this knowledge and new immunotherapies. We will first describe the main activities of the immune system, to continue with the treatment of bladder cancer with BCG, its mechanism of action and biomarkers. Finally, we will summarize the observations that led to the useof monoclonal antibody immunotherapy in cancer and will describe some of the new immunotherapies in use to treat bladder cancer patients.
Insights
Bladder cancer immunotherapy, like Bacillus Calmette-Guérin (BCG), harnesses the immune system. Understanding its mechanisms can improve treatments and predict patient responses to new immunotherapies.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Bladder cancer treatment has historically benefited from immune stimulation.
- Bladder tumors exhibit high antigenicity, suggesting susceptibility to immunotherapy.
- Studying immune responses to bladder cancer treatment informs current and future therapies.
Purpose of the Study:
- To examine the immune response to Bacillus Calmette-Guérin (BCG) treatment in non-muscle invasive bladder cancer.
- To correlate BCG treatment mechanisms with emerging immunotherapies.
- To understand patient variability in response and tolerance to immunotherapy.
Main Methods:
- Review of immune system activities relevant to cancer.
- Analysis of BCG treatment for bladder cancer, including mechanism of action and biomarkers.
- Summary of historical observations leading to monoclonal antibody immunotherapy.
- Description of current immunotherapies for bladder cancer.
Main Results:
- BCG treatment stimulates an immune response in bladder cancer.
- High antigenic load in bladder tumors predicts immunotherapy response.
- Variability in patient response and tolerance to immunotherapy is observed.
Conclusions:
- Understanding BCG's mechanism provides insights into bladder cancer immunotherapy.
- New immunotherapies, including monoclonal antibodies, are advancing bladder cancer treatment.
- Further research is needed to optimize immunotherapy efficacy and patient selection.
